Moderna (MRNA) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

BofA lifted its price target to $27 from $24 while keeping an 'Underperform' rating on the shares. ・The update followed the release of five-year follow-up results for the Intismeran vaccine used ...

If you are wondering whether Moderna's share price still reflects its underlying worth, it helps to start with the recent ...

Moderna shares are down on Monday, pulling back following a recent report highlighting its latest cancer trial results.

Moderna Inc (NASDAQ:MRNA) shares are trading higher on Wednesday on continued momentum after the company's Tuesday update revealing the long‑term results from a cancer therapy study.

What Is Driving the Updated Fair Value for Moderna? Analyst models on Moderna have been refreshed, with the fair value ...

The vaccine maker is expanding beyond its COVID-focused offerings.

Investing.com -- Moderna (NASDAQ:MRNA) stock rose 10% on Thursday, extending its winning streak to a fourth consecutive session and reaching its highest intraday level since November 2024.

MIAMI, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Defiance ETFs today announced the launch of the Defiance Daily Target 2X Long MRNA ETF (MRNX), expanding its lineup of single-stock leveraged ETFs designed for ...